Photo of Linda C. Stork, M.D.

Linda C. Stork M.D.

    • Professor of Pediatrics, Division of Hematology and Oncology School of Medicine
    • Robert C. Neerhout Chair of Pediatric Oncology Pediatrics School of Medicine

Dr. Stork is expert in the diagnosis and treatment of cancers in children and adolescents. She has a particular interest in leukemias, lymphomas, and promising new cancer treatments. Dr. Stork is married to Christopher Shiner and has one son, Austin, who is attending college. She enjoys living in Portland, travel and exposure to diverse cultures, the performing arts, and eating delicious meals cooked by her husband and son.

Education

  • M.D., Columbia University College of Physicians & Surgeons 1979
  • Residency:

    • Pediatrics, Columbia University – Babies Hospital, NYC, NY, 1981 Pediatrics, U of Colorado Health Sciences Center, Denver, CO 1982
  • Fellowship:

    • Pediatric hematology/oncology, U of Colorado Health Sciences Center, Denver, CO 1986
  • Certifications:

    • American Board of Pediatrics, 1985
    • American Board of Pediatric Hematology/Oncology, 1987, 2015

Memberships and associations

  • American Society of Pediatric Hematology/Oncology
  • American Society of Hematology
  • American Society of Oncology
  • Children's Oncology Group
  • International Society of Pediatric Oncology

Publications

  • "Dexamethasone chemotherapy does not disrupt orexin signaling." PLoS ONE In: , Vol. 11, No. 12, e0168731, 01.12.2016.
  • "Navigating your career path in pediatric hematology/oncology : On and off the beaten track." Pediatric Blood and Cancer In: , Vol. 63, No. 10, 01.10.2016, p. 1723-1730.
  • "Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia—Comparison among Different Treatment Strategies." Pediatric Blood and Cancer In: , Vol. 63, No. 2, 01.02.2016, p. 255-261.
  • "Early career mentoring through the American Society of Pediatric Hematology/Oncology : Lessons learned from a pilot program." Pediatric Blood and Cancer In: , 2016.
  • "Reply to : Obesity is an important health problem in survivors of pediatric acute lymphoblastic leukemia." Pediatric Blood and Cancer In: , Vol. 62, No. 11, 01.11.2015, p. 2057.
  • "Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML)." Pediatric Blood and Cancer  In: , Vol. 62, No. 7, 01.07.2015, p. 1149-1154.
  • "Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non-cancer peers : A report from the Children's Oncology Group." Pediatric Blood and Cancer In: , Vol. 62, No. 6, 01.06.2015, p. 1035-1041.
  • "Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952." Leukemia Research Reports  In: , Vol. 4, No. 2, 27.05.2015, p. 47-50.
  • "Family life events in the first year of acute lymphoblastic leukemia therapy : A children's oncology group report." Pediatric Blood and Cancer  In: , Vol. 61, No. 12, 01.12.2014, p. 2277-2284.
  • "TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia : A report from the Children's Oncology Group." Pediatric Blood and Cancer  In: , Vol. 61, No. 11, 01.11.2014, p. 2086-2088.
  • "Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease." Pediatric Blood and Cancer In: , Vol. 61, No. 3, 03.2014, p. 479-487.
  • "Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia." Pediatric Blood and Cancer In: , Vol. 59, No. 5, 11.2012, p. 840-845.
  • "Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph +ALL : A Children's Oncology Group (COG) study." British Journal of Haematology In: , Vol. 157, No. 4, 05.2012, p. 507-510.
  • "Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia : A report from the Children's Oncology Group." Blood In: , Vol. 118, No. 2, 14.07.2011, p. 243-251.
  • "Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia." Leukemia In: , Vol. 25, No. 6, 06.2011, p. 953-959.
  • "Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia : Report of the Children's Oncology Group CCG-1952 clinical trial." Blood In: , Vol. 115, No. 14, 08.04.2010, p. 2740-2748.
  • "Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia." Journal of Clinical Oncology In: , Vol. 27, No. 35, 10.12.2009, p. 5986-5992.
  • "Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia." Pediatric Blood and Cancer  In: , Vol. 53, No. 4, 10.2009, p. 543-550.
  • "Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)." Pediatric Blood and Cancer  In: , Vol. 52, No. 7, 01.07.2009, p. 847-852.
  • "A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia." Blood In: , Vol. 114, No. 9, 2009, p. 1746-1752.
  • "A unique case of adolescent CD56-negative extranodal NK/T-cell lymphoma, nasal type." Pediatric and Developmental Pathology  In: , Vol. 11, No. 1, 01.2008, p. 50-54.
  • "Outcome after relapse among children with standard-risk acute lymphoblastic leukemia : Children's Oncology Group Study CCG-1952." Journal of Clinical Oncology In: , Vol. 25, No. 36, 20.12.2007, p. 5800-5807.
  • "Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia : A collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942)." Pediatric Blood and Cancer In: , Vol. 49, No. 3, 09.2007, p. 250-255.
  • "Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors : The Children's Oncology Group." Journal of Clinical Oncology In: , Vol. 25, No. 12, 20.04.2007, p. 1505-1511.
  • "Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate : Results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group." Blood In: , Vol. 108, No. 4, 15.08.2006, p. 1165-1173.
  • "Toxicity due to 6-thioquanine [4] (multiple letters)." Pediatric Blood and Cancer  In: , Vol. 45, No. 6, 10.2005, p. 867-868.
  • "Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy." Pediatric Blood and Cancer  In: , Vol. 44, No. 3, 03.2005, p. 226-231.
  • "Lymphoblast biology and outcome among children with down syndrome and ALL treated on CCG-1952." Pediatric Blood and Cancer In: , Vol. 44, No. 1, 01.2005, p. 21-28.
  • "A Case of Childhood Peripheral T-Cell Lymphoma with Massive Cardiac Infiltration." Journal of Pediatric Hematology/Oncology  In: , Vol. 26, No. 1, 01.2004, p. 48-51.
  • "Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells." Leukemia Research In: , Vol. 27, No. 12, 01.12.2003, p. 1135-1142.

Additional information

Edit profile